CoChat

Niacin dosing: Relationship to benefits and adverse effects

Capuzzi, David M., Morgan, John M., Brusco, Osvaldo A., Intenzo, Charles M. · 2000 · Current Atherosclerosis Reports

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Because of the original observation by Altschul et al., that nicotinic acid (niacin), not nicotinamide, in pharmacologic doses lowered human serum cholesterol levels, an avalanche of reports have been published over the past 45 years on the plasma lipid-regulating properties of this drug and its beneficial cardiovascular effects. A myriad of studies that have examined efficacy, safety, adverse effects, and pharmacologic properties of niacin rendered convincing evidence that niacin, used alone or combined with other agents, has favorable effects on serum lipoprotein regulation and on containment of atherothrombotic cardiovascular diseases. However, because of the unusual side effect profile of niacin and the availability of various formulations of this drug, niacin must be used prudently and with careful instruction and monitoring of patients. This review summarizes the pertinent and recent literature on niacin that impacts its therapeutic use. We also discuss some controversial issues and personal clinical experience and opinions on this topic.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-000-0096-y

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 2

  1. Morgan JM, Capuzzi DM, Guyton JR, et al.: Treatment effect of niaspan, a controlled-release niacin, in patients with hypercholesterolemia:a placebo controlled trial. J Cardiovasc Pharmacol Therapeut 1996, 1:195–202. · DOI · Paper page
  2. Brusco OA, Capuzzi DM, Morgan, JM, et al.: Incidence of primary lipoprotein abnormalities and lipoprotein (a) excess in referred out-patients with premature CHD. CA J Invest Med 1995, 43 (Suppl 2):390A.

Cited by

See all 93

Metadata

Authors
Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M.
Affiliations
Thomas Jefferson University (US)
Venue
Current Atherosclerosis Reports
Published
2000-12
Volume
2
Issue
1
Pages
64-71
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W1984146279
Cited by
88
References
39
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 3 · 2019: 4 · 2018: 2 · 2017: 1 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 4 · 2012: 5
FWCI
0.57
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Nursing › Nutrition and Dietetics › Folate and B Vitamins Research
Keywords
nicotinic acid, dosage, adverse effects, hypercholesterolemia, serum lipoproteins, cardiovascular disease prevention, atherothrombosis, drug safety, lipid-lowering therapy
MeSH terms
Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Hypercholesterolemia, Niacin, Lipid Metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Niacin dosing: Relationship to benefits and adverse effects. https://app.cochat.ai/papers/10.1007/s11883-000-0096-y
The paper
Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M. (2000). Niacin dosing: Relationship to benefits and adverse effects. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-000-0096-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.